Loading…
Neurological complications of infliximab
The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis (RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients who developed neurological disease closely as...
Saved in:
| Published in: | Journal of rheumatology 2006-05, Vol.33 (5), p.1018-1020 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | 1020 |
| container_issue | 5 |
| container_start_page | 1018 |
| container_title | Journal of rheumatology |
| container_volume | 33 |
| creator | JARAND, Julie ZOCHODNE, Douglas W MARTIN, Liam O VOLL, Christopher |
| description | The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis
(RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients
who developed neurological disease closely associated with the use of infliximab, a monoclonal antibody that binds to and
inactivates TNF-a. All had evidence of polyneuropathy, demyelinating in one and axonal in 2. One patient had a central nervous
system syndrome. Physicians should be aware of these potential adverse effects when treating patients with infliximab. |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_16511935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16511935</sourcerecordid><originalsourceid>FETCH-LOGICAL-h270t-52994b84514554b4554e9eb3a283db09f02fabfa2bc27f9daed1b0fb43c8785b3</originalsourceid><addsrcrecordid>eNpFjktLxDAUhYMoTh39C9KN4qaQm0ebLGXQURh0o-AuJG0yjaQPmhmq_97IjLg59yw-vntOUAZMyoJUnJyiDFPgBZTkY4EuYvzEGEpWinO0gJIDSMozdPdi99MQhq2vdcjroRtDajs_9DEfXO57F_yX77S5RGdOh2ivjneJ3h8f3lZPxeZ1_by63xQtqfCu4ERKZgTjwDhn5jestIZqImhjsHSYOG2cJqYmlZONtg0Y7AyjtagEN3SJrg_ecW8626hxSt-nb_U3OQE3R0DHtNlNuq99_OeqpJElSdztgWv9tp39ZFXsdAhJS9U8z5QqrgCDoD_n6Vf_</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Neurological complications of infliximab</title><source>Medical Journals (Open access)</source><creator>JARAND, Julie ; ZOCHODNE, Douglas W ; MARTIN, Liam O ; VOLL, Christopher</creator><creatorcontrib>JARAND, Julie ; ZOCHODNE, Douglas W ; MARTIN, Liam O ; VOLL, Christopher</creatorcontrib><description>The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis
(RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients
who developed neurological disease closely associated with the use of infliximab, a monoclonal antibody that binds to and
inactivates TNF-a. All had evidence of polyneuropathy, demyelinating in one and axonal in 2. One patient had a central nervous
system syndrome. Physicians should be aware of these potential adverse effects when treating patients with infliximab.</description><identifier>ISSN: 0315-162X</identifier><identifier>EISSN: 1499-2752</identifier><identifier>PMID: 16511935</identifier><identifier>CODEN: JRHUA9</identifier><language>eng</language><publisher>Toronto, ON: The Journal of Rheumatology</publisher><subject>Aged ; Aged, 80 and over ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antirheumatic Agents - adverse effects ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - drug therapy ; Biological and medical sciences ; Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction ; Demyelinating Diseases - chemically induced ; Demyelinating Diseases - pathology ; Demyelinating Diseases - physiopathology ; Diseases of the osteoarticular system ; Female ; Humans ; Inflammatory joint diseases ; Infliximab ; Medical sciences ; Middle Aged ; Nervous system (semeiology, syndromes) ; Nervous System - drug effects ; Nervous System - pathology ; Nervous System - physiopathology ; Nervous system as a whole ; Neurology ; Polyneuropathies - chemically induced ; Polyneuropathies - pathology ; Polyneuropathies - physiopathology</subject><ispartof>Journal of rheumatology, 2006-05, Vol.33 (5), p.1018-1020</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17785962$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16511935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JARAND, Julie</creatorcontrib><creatorcontrib>ZOCHODNE, Douglas W</creatorcontrib><creatorcontrib>MARTIN, Liam O</creatorcontrib><creatorcontrib>VOLL, Christopher</creatorcontrib><title>Neurological complications of infliximab</title><title>Journal of rheumatology</title><addtitle>J Rheumatol</addtitle><description>The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis
(RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients
who developed neurological disease closely associated with the use of infliximab, a monoclonal antibody that binds to and
inactivates TNF-a. All had evidence of polyneuropathy, demyelinating in one and axonal in 2. One patient had a central nervous
system syndrome. Physicians should be aware of these potential adverse effects when treating patients with infliximab.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antirheumatic Agents - adverse effects</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction</subject><subject>Demyelinating Diseases - chemically induced</subject><subject>Demyelinating Diseases - pathology</subject><subject>Demyelinating Diseases - physiopathology</subject><subject>Diseases of the osteoarticular system</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Infliximab</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Nervous System - drug effects</subject><subject>Nervous System - pathology</subject><subject>Nervous System - physiopathology</subject><subject>Nervous system as a whole</subject><subject>Neurology</subject><subject>Polyneuropathies - chemically induced</subject><subject>Polyneuropathies - pathology</subject><subject>Polyneuropathies - physiopathology</subject><issn>0315-162X</issn><issn>1499-2752</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpFjktLxDAUhYMoTh39C9KN4qaQm0ebLGXQURh0o-AuJG0yjaQPmhmq_97IjLg59yw-vntOUAZMyoJUnJyiDFPgBZTkY4EuYvzEGEpWinO0gJIDSMozdPdi99MQhq2vdcjroRtDajs_9DEfXO57F_yX77S5RGdOh2ivjneJ3h8f3lZPxeZ1_by63xQtqfCu4ERKZgTjwDhn5jestIZqImhjsHSYOG2cJqYmlZONtg0Y7AyjtagEN3SJrg_ecW8626hxSt-nb_U3OQE3R0DHtNlNuq99_OeqpJElSdztgWv9tp39ZFXsdAhJS9U8z5QqrgCDoD_n6Vf_</recordid><startdate>20060501</startdate><enddate>20060501</enddate><creator>JARAND, Julie</creator><creator>ZOCHODNE, Douglas W</creator><creator>MARTIN, Liam O</creator><creator>VOLL, Christopher</creator><general>The Journal of Rheumatology</general><general>Journal of Rheumatology Publishing</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20060501</creationdate><title>Neurological complications of infliximab</title><author>JARAND, Julie ; ZOCHODNE, Douglas W ; MARTIN, Liam O ; VOLL, Christopher</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h270t-52994b84514554b4554e9eb3a283db09f02fabfa2bc27f9daed1b0fb43c8785b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antirheumatic Agents - adverse effects</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction</topic><topic>Demyelinating Diseases - chemically induced</topic><topic>Demyelinating Diseases - pathology</topic><topic>Demyelinating Diseases - physiopathology</topic><topic>Diseases of the osteoarticular system</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Infliximab</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Nervous System - drug effects</topic><topic>Nervous System - pathology</topic><topic>Nervous System - physiopathology</topic><topic>Nervous system as a whole</topic><topic>Neurology</topic><topic>Polyneuropathies - chemically induced</topic><topic>Polyneuropathies - pathology</topic><topic>Polyneuropathies - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JARAND, Julie</creatorcontrib><creatorcontrib>ZOCHODNE, Douglas W</creatorcontrib><creatorcontrib>MARTIN, Liam O</creatorcontrib><creatorcontrib>VOLL, Christopher</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JARAND, Julie</au><au>ZOCHODNE, Douglas W</au><au>MARTIN, Liam O</au><au>VOLL, Christopher</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neurological complications of infliximab</atitle><jtitle>Journal of rheumatology</jtitle><addtitle>J Rheumatol</addtitle><date>2006-05-01</date><risdate>2006</risdate><volume>33</volume><issue>5</issue><spage>1018</spage><epage>1020</epage><pages>1018-1020</pages><issn>0315-162X</issn><eissn>1499-2752</eissn><coden>JRHUA9</coden><abstract>The use of anti-tumor necrosis factor-a (TNF-a) therapies has led to improved outcomes in the treatment of rheumatoid arthritis
(RA). However, the use of these new therapeutic agents requires careful monitoring for adverse effects. We describe 3 patients
who developed neurological disease closely associated with the use of infliximab, a monoclonal antibody that binds to and
inactivates TNF-a. All had evidence of polyneuropathy, demyelinating in one and axonal in 2. One patient had a central nervous
system syndrome. Physicians should be aware of these potential adverse effects when treating patients with infliximab.</abstract><cop>Toronto, ON</cop><pub>The Journal of Rheumatology</pub><pmid>16511935</pmid><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0315-162X |
| ispartof | Journal of rheumatology, 2006-05, Vol.33 (5), p.1018-1020 |
| issn | 0315-162X 1499-2752 |
| language | eng |
| recordid | cdi_pubmed_primary_16511935 |
| source | Medical Journals (Open access) |
| subjects | Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - drug therapy Biological and medical sciences Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction Demyelinating Diseases - chemically induced Demyelinating Diseases - pathology Demyelinating Diseases - physiopathology Diseases of the osteoarticular system Female Humans Inflammatory joint diseases Infliximab Medical sciences Middle Aged Nervous system (semeiology, syndromes) Nervous System - drug effects Nervous System - pathology Nervous System - physiopathology Nervous system as a whole Neurology Polyneuropathies - chemically induced Polyneuropathies - pathology Polyneuropathies - physiopathology |
| title | Neurological complications of infliximab |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A07%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neurological%20complications%20of%20infliximab&rft.jtitle=Journal%20of%20rheumatology&rft.au=JARAND,%20Julie&rft.date=2006-05-01&rft.volume=33&rft.issue=5&rft.spage=1018&rft.epage=1020&rft.pages=1018-1020&rft.issn=0315-162X&rft.eissn=1499-2752&rft.coden=JRHUA9&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E16511935%3C/pubmed_pasca%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-h270t-52994b84514554b4554e9eb3a283db09f02fabfa2bc27f9daed1b0fb43c8785b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/16511935&rfr_iscdi=true |